RecruitingNCT07270861

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma

Sponsor

Fudan University

Enrollment

3,000 participants

Start Date

Nov 15, 2025

Study Type

OBSERVATIONAL

Conditions

Peripheral T Cell Lymphoma

Summary

This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting real-world data on patients with peripheral T-cell lymphoma (PTCL), a rare and aggressive type of blood cancer, to better understand how different treatments affect outcomes over time. It includes both patients treated in the past (going back to 2010) and newly diagnosed patients going forward. **You may be eligible if...** - You are 18 or older - You have been diagnosed with peripheral T-cell lymphoma (any subtype) confirmed by tissue biopsy - For the historical group: you were diagnosed and treated at a participating center between 2010 and 2024 - For the prospective group: you are newly diagnosed from October 2025 onward **You may NOT be eligible if...** - Your T-cell lymphoma has not been confirmed by pathology - You are under 18 - You were treated at a non-participating center (for the retrospective cohort) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.